Valneva

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Immune response successfully improved with second generation vaccine candidate4 November 2025 -- Saint-Herblain, France -- Valneva SE, a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). The randomized controlled Phase 1 trial,...

Valneva Scotland Receives Prestigious Award for Health and Safety Excellence

8 August 2024 -- Scotland, UK -- Scotland's largest vaccine producer, Valneva Scotland Ltd, based in Livingston, has achieved an esteemed Silver Award for health and safety from the Royal Society for the Prevention of Accidents (RoSPA). These international awards recognise the highest standards of safety and excellence within the workplace, assessing health and safety...
6 rue Alain Bombard, 44800 Saint-Herblain, France

+33 2 28 07 37 10